Data indicates that 30-40% of the US population complains of transient sleep disorders and that one in ten adults experience periods of chronic sleep issues. The prevalence of insomnia is estimated to be between 35 and 50% of adults. Adequate, restful sleep is essential to the body's well being. Insomnia is defined as having difficulty falling asleep, having difficulty maintaining sleep, awakening too early, and/or experiencing poor quality, non-refreshing sleep.

Zolpimist Oral Spray is a novel delivery system of zolpidem tartrate, the most widely prescribed agent in the US for treating insomnia. Zolpimist is sprayed over the tongue and on the back of the mouth where it is absorbed by the oral mucosa and gastrointestinal tract. The product is not inhaled. Due to Zolpimist's rapid absorption it should only be administered immediately before going to bed. Patients should use Zolpimist when they expect to be able to stay in bed for a full night (7-8 hours).

The most common adverse events associated with Zolpimist and zolpidem tartrate are headache, drowsiness, dizziness, and diarrhea. For a complete listing of reported adverse events or for additional information, consult the appended Zolpimist Oral Spray Full Prescribing Information.

Patients should consult the appended Patient Instructions for Use and Medication Guide prior to taking Zolpimist.

Zolpimist Oral Spray is dispensed in a child resistant container. The unit must be primed prior to its initial use. The unit does not require re-priming unless it has not been used for more than 14 days.
Please see Patient Instructions for Use for priming instructions.

Each Zolpimist unit contains 60-5 mg sprays, after priming. The usual adult dosage of Zolpimist is 2 sprays (10 mg) but may be adjusted downward to meet the patient's needs.. The recommended dose of Zolpimist in patients over 65 years is one spray (5 mg). Take Zolpimist exactly as prescribed by your physician.

Certification of Compliance